← Leaderboards
Yuan Liu
University Of Pittsburgh At Pittsburgh
$4,548,206
Attributed
$6,738,082
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,738,082 · 3
By mechanism
R01$6,738,082 · 3
Top collaborators
- Michael J. Jurczak5 shared
- Simon M Barratt-Boyes3 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Michael J. Jurczak$3,728,877
- Jaideep Behari$4,660,334
- Michael S. Diamond$85,358,908
- Katalin None Szanto$10,528,387
- Nicholas Khoo$680,523
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingPathway InteractionsFunctional DisorderUbiquitin-Protein LigaseSmall MoleculeProteinsCellsMolecularRecruitKnock-DownInflammatorySignal TransductionPreventOverexpressionInflammationPharmaceutical PreparationsBaseProtein DegradationAnimal ModelLibrariesMass Spectrum AnalysisLungLysosomesBacteria
Grant awards (13)
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome$779,817
R01 · FY2025 · AI · contact PI
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome$785,479
R01 · FY2024 · AI · contact PI
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome$765,082
R01 · FY2023 · AI · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2023 · DK
DCAF7/HDAC4/TFEB axis in acute lung injury$471,666
R01 · FY2022 · HL · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2022 · DK
DCAF7/HDAC4/TFEB axis in acute lung injury$471,666
R01 · FY2021 · HL · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$414,914
R01 · FY2021 · DK
DCAF7/HDAC4/TFEB axis in acute lung injury$471,666
R01 · FY2020 · HL · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2020 · DK
DCAF7/HDAC4/TFEB axis in acute lung injury$471,666
R01 · FY2019 · HL · contact PI
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD$408,615
R01 · FY2019 · DK
DCAF7/HDAC4/TFEB axis in acute lung injury$471,666
R01 · FY2018 · HL · contact PI